MK-507 versus Sezolamide: Comparative Efficacy of Two Topically Active Carbonic Anhydrase Inhibitors

Erik A. Lippa, Joel S. Schuman, Eve J. Higginbotham, Michael A. Kass, Robert N. Weinreb, Gregory L. Skuta, David L. Epstein, Blake Shaw, Daniel J. Holder, Deni A. Deasy, Jacob T. Wilensky

    Research output: Contribution to journalArticle

    Abstract

    Topical carbonic anhydrase inhibitors MK-507 and sezolamide hydrochloride (previously known as MK-417) were compared in a double-masked, randomized, placebo-controlled study in 82 patients with bilateral primary openangle glaucoma or ocular hypertension. MK-507 was given every 8 or 12, hours, sezolamide every 8 hours, or placebo every 8 or 12 hours for 4 days. Both drugs lowered intraocular pressure (IOP) substantially. MK-507 was somewhat more active than sezolamide, with a peak mean IOP reduction of 26.2% for MK-507 versus 22.5% for sezolamide, although the difference between the treatments was not statistically significant. These drugs may have potential in the treatment of glaucoma.

    Original languageEnglish (US)
    Pages (from-to)308-313
    Number of pages6
    JournalOphthalmology
    Volume98
    Issue number3
    DOIs
    StatePublished - 1991

    ASJC Scopus subject areas

    • Ophthalmology

    Fingerprint Dive into the research topics of 'MK-507 versus Sezolamide: Comparative Efficacy of Two Topically Active Carbonic Anhydrase Inhibitors'. Together they form a unique fingerprint.

  • Cite this

    Lippa, E. A., Schuman, J. S., Higginbotham, E. J., Kass, M. A., Weinreb, R. N., Skuta, G. L., Epstein, D. L., Shaw, B., Holder, D. J., Deasy, D. A., & Wilensky, J. T. (1991). MK-507 versus Sezolamide: Comparative Efficacy of Two Topically Active Carbonic Anhydrase Inhibitors. Ophthalmology, 98(3), 308-313. https://doi.org/10.1016/S0161-6420(91)32295-4